Table 4.
Viscoelastic coagulation parameters from ex vivo study, in which five concentrations of acepromazine were added to native whole blood during collection. p-values indicate results from two-way repeated measures ANOVA for effects of concentration (CONC) and horse; * denotes statistical significance.
| 1000 ng/mL | 500 ng/mL | 250 ng/mL | 125 ng/mL | 62.5 ng/mL | 0 ng/mL | Conc | Horse | |
|---|---|---|---|---|---|---|---|---|
| CT (s) | 974 (884, 1056) | 900 (849, 910) | 850 (837, 982) | 877 (790, 984) | 809 (806, 886) | 908 (778, 977) | 0.207 | <0.001 * |
| CFT (s) | 381 (350, 428) | 287 (234, 326) | 351 (318, 425) | 380 (317, 447) | 363 (319, 410) | 276 (212, 437) | 0.972 | 0.023 * |
| Alpha (deg) |
31.5 (26, 37) | 35 (32, 39) | 36 (31, 37) | 31 (29, 34) | 31 (30, 34) | 40 (29, 48) | 0.3 | <0.001 * |
| A10 (VCM units) |
14.5 (13, 16) | 19 (18, 20) | 14 (13, 17) | 14 (13 17) | 17 (15, 19) | 22 (17, 24) | 0.452 | 0.158 |
| A20 (VCM units) |
20 (18, 22) | 25 (24, 27) | 18 (18, 22) | 18 (17, 21) | 22 (20, 24) | 28 (24, 28) | 0.654 | 0.094 |
| MCF (VCM units) |
20 (19, 24) | 25 (24, 27) | 18 (18, 22) | 19 (17, 22) | 23 (21, 24) | 28 (24, 28) | 0.891 | 0.297 |
| LI30 (%) | 100 (94, 100) | 100 (99, 100) | 100 (100, 100) | 100 (100, 100) | 100 (100, 100) | 100 (100, 100) | 0.063 | 0.329 |
| LI45 (%) | 94 (94, 94) | 93 (93, 93) | 94 (94, 94) | 95 (94, 96) | 94 (93, 97) | 92 (89, 94) | 1 | 0.238 |
Abbreviations: CFT, clot formation time; CT, clot time; LI, clot lysis; MCF, maximum clot formation.